CardioInsight Announces Addition of Jim Hassett to Senior Management Team

CLEVELAND, Feb. 28, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Jim Hassett as its Vice President of Clinical Affairs.

(Logo:  http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)

Mr. Hassett brings more than 30 years of product development, clinical development and regulatory affairs experience in the field of cardiac rhythm management to CardioInsight.  His previous roles include senior management level positions in clinical and therapy development, most notably at Daig Corporation and subsequently at St Jude Medical, where he held Vice President positions in the AF Division.  Mr. Hassett has successfully managed the development and clinical introduction of a number of innovative electrophysiology products that include cardiac mapping, arrhythmia ablation, and heart failure devices.

"I have been aware of CardioInsight's technology for a number of years, and have been impressed with its development into a commercial product," said Mr. Hassett.  "The ECVUE™  system addresses a clear unmet need in the treatment of arrhythmias and other electrical disorders of the heart, and I look forward to helping make this system a valuable clinical tool in everyday electrophysiology practice."

CardioInsight recently announced the commercial introduction of its ECVUE non-invasive cardiac mapping system in Europe, and is working to demonstrate the clinical utility of the system in a commercial setting.   In the coming year, the Company will pursue regulatory clearance in the U.S., as well as accelerate its clinical development efforts to further validate its unique ability to simplify cardiac mapping procedures, reduce procedure times, and expand the use of mapping to new applications, including cardiac resynchronization therapy (CRT).

"Jim's extensive clinical development experience, coupled with his strong reputation working with the FDA and clinical thought leaders throughout the world will be an invaluable asset as we accelerate our clinical development," said Steve Arless, CardioInsight's Chief Executive Officer. "The ability to attract someone of Jim's caliber is further validation of the potential of the ECVUE system, and CardioInsight's continued evolution to a commercial stage company."

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.
 The images help physicians more accurately treat certain heart ailments such as arrhythmias
and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of
the electrical activity on the surface of the heart by combining body surface electrical data with
3D anatomical data obtained from imaging scans. It then reconstructs and
displays 3D images and other useful measures of cardiac electrical activity as if the
measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.

SOURCE CardioInsight Technologies Inc.